Stockscreener 앱 받기
4.30
4.66%
-0.21
시간 외 거래:
4.38
0.08
+1.86%
전일 마감가:
$4.51
열려 있는:
$4.54
하루 거래량:
116.47K
Relative Volume:
0.38
시가총액:
$242.80M
수익:
$2.76M
순이익/손실:
$-49.12M
주가수익비율:
-2.8667
EPS:
-1.5
순현금흐름:
$-46.21M
1주 성능:
-2.05%
1개월 성능:
+9.14%
6개월 성능:
+39.16%
1년 성능:
-18.25%
1일 변동 폭
$4.2598
$4.64
1주일 범위
$4.19
$4.69
52주 변동 폭
$2.20
$6.30
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
OBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.30 | 254.66M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | TD Cowen | Buy |
| 2025-08-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
Orchestra BioMed (NASDAQ:OBIO) Now Covered by Analysts at TD Cowen - Defense World
TD Cowen Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy Recommendation - Nasdaq
TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio - Investing.com Nigeria
TD Cowen Initiates Orchestra BioMed Holdings at Buy With $15 Price Target - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances - Zenopa
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - Investing News Network
Orchestra BioMed announces AVIM Therapy and Virtue SAB Program presentations at ICI Meeting - marketscreener.com
Orchestra BioMed and Medtronic Leadership to Present on Strategic Collaboration for AVIM Therapy at 2025 Innovation in Cardiology Intervention Meeting - Quiver Quantitative
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MSN
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements - MSN
What insider trading reveals about Orchestra BioMed Holdings Inc. stockShort Setup & AI Powered Market Trend Analysis - Newser
Orchestra BioMed Enters New Agreement with Terumo for Virtue SAB Device - globallegalchronicle.com
Wall Street Recap: Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growth2025 Macro Impact & Weekly High Return Stock Forecasts - moha.gov.vn
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
A better buy-in window may exist right now for Orchestra BioMed Holdings Inc (OBIO) - Setenews
Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growth2025 Buyback Activity & Fast Momentum Stock Entry Tips - BỘ NỘI VỤ
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Orchestra BioMed Holdings Inc. stock performs in high volatility marketsWeekly Trade Report & Verified Short-Term Plans - moha.gov.vn
Orchestra Biomed announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Orchestra BioMed Grants Stock Options to New Hires as Part of 2025 Inducement Plan - Quiver Quantitative
Orchestra BioMed Holdings Insiders May Regret Not Buying More, Market Cap Hits US$273m - 富途牛牛
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials - MSN
How currency fluctuations impact Orchestra BioMed Holdings Inc. stockDividend Hike & Low Drawdown Trading Strategies - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 2025July 2025 Snapshot & Entry and Exit Point Strategies - newser.com
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease - MSN
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Is Orchestra BioMed Holdings Inc. stock supported by strong cash flowsWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Is Orchestra BioMed Ready For Landmark Year With Trial Enrollment And Cash Strength? - RTTNews
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.2025 Volatility Report & Expert Curated Trade Setups - newser.com
Orchestra BioMed Holdings Director David P Hochman Acquires 5,000 Shares - TradingView
Chmn Hochman Buys 5,000 ($20.4K) Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity - Stock Titan
Is this a good reentry point in Orchestra BioMed Holdings Inc.Day Trade & Free Verified High Yield Trade Plans - newser.com
Research Analysts Offer Predictions for OBIO FY2025 Earnings - Defense World
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight Recommendation - MSN
Will Orchestra BioMed Holdings Inc. stock recover after recent drop2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Can Orchestra BioMed Holdings Inc. stock withstand economic slowdownJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Chmn Hochman Surrenders 6,566 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
Views of Wall Street’s Leading Experts on Orchestra BioMed Holdings Inc - setenews.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon - MSN
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):